论文部分内容阅读
人社厅函[2011]558号各省、自治区、直辖市人力资源社会保障厅(局),新疆生产建设兵团劳动保障局:近期,国家食品药品监督管理局下发通知,停止阿米三嗪萝巴新片(复方阿米三嗪片)和盐酸克仑特罗片剂在我国的生产销售使用。为保证广大参保人员用药安全,现就有关问题通知如下:一、自发文之日起,删除《国家基本医疗保险、工伤保险和生育保险药品目录(2009年版)》中的“阿米三嗪萝巴新口服常释剂型”(西药第526号)和“克仑特罗口服常释剂型”(西药第657号)。
Human Resources and Social Security Bureau (Bureau) of Human Resources and Social Security of All Provinces, Autonomous Regions and Municipalities directly under the Central Government and Labor and Social Security Bureau of Xinjiang Production and Construction Corps: Recently, the State Food and Drug Administration issued a circular notifying the resumption of amylazine The new film (compound amilizide tablets) and clenbuterol tablets in the production and marketing of our use. In order to ensure the safety of the majority of insured persons, we hereby notify you of the relevant issues as follows: 1. As of the date of publication, the names of the “National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2009 Edition)” in the “ The new oral administration of nerolizin oral formulations ”(Western medicine No. 526) and “ Clenbuterol oral sustained release formulations ”(Western medicine No. 657).